Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome
Maisa Yoshimoto(University of Alberta), Jeremy A. Squire(Universidade de São Paulo), Isabela Werneck da Cunha(AC Camargo Hospital), Fernando Augusto Soares(University of Connecticut), Anthony M. Joshua(St Vincent's Hospital Sydney), Maria Zieleńska(University of Toronto), Renata A. Coudry(AC Camargo Hospital), F.P. Fonseca(AC Camargo Hospital), Olga Ludkovski
Cited by 278
Related Papers
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
|JAMA|2016|1.1k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869